MWVC
Morgens Waterfall Vintiadis & Co Portfolio holdings
AUM
$136M
This Quarter Return
+0.87%
1 Year Return
+103.3%
3 Year Return
+567.71%
5 Year Return
+1,003.82%
10 Year Return
+9,424.15%
AUM
$107M
AUM Growth
+$107M
(-25%)
Cap. Flow
-$30.5M
Cap. Flow
% of AUM
-28.56%
Top 10 Holdings %
Top 10 Hldgs %
52.72%
Holding
54
New
6
Increased
4
Reduced
18
Closed
24
Top Buys
| 1 |
Costco
COST
|
$3.42M |
| 2 |
Apple
AAPL
|
$2.8M |
| 3 |
Nike
NKE
|
$2.65M |
| 4 |
MLNX
Mellanox Technologies, Ltd.
MLNX
|
$2.43M |
| 5 |
Freshpet
FRPT
|
$2.3M |
Top Sells
| 1 |
Caesars Entertainment
CZR
|
$4.77M |
| 2 |
Take-Two Interactive
TTWO
|
$4.62M |
| 3 |
Advanced Micro Devices
AMD
|
$4.59M |
| 4 |
PARA
Paramount Global Class B
PARA
|
$3.69M |
| 5 |
Wynn Resorts
WYNN
|
$3.54M |
Sector Composition
| 1 | Technology | 48.09% |
| 2 | Consumer Discretionary | 19.4% |
| 3 | Communication Services | 12.24% |
| 4 | Consumer Staples | 9.41% |
| 5 | Financials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Visa
V
$683B
| $1.14M | 1.07% |
7,100
-5,800
| -45% | -$935K |
|
|
RETA
27
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $866K | 0.81% |
6,000
-22,600
| -79% | -$3.26M |
|
28
Mastercard
MA
$538B
| $773K | 0.72% |
3,200
-3,300
| -51% | -$797K |
|
29
AstraZeneca
AZN
$248B
| $500K | 0.47% |
11,200
-1,700
| -13% | -$75.9K |
|
30
JPMorgan Chase
JPM
$829B
| $350K | 0.33% |
3,893
-682
| -15% | -$61.3K |
|
31
ADMA Biologics
ADMA
$4.12B
| – | – |
-600,000
| Closed | -$2.4M |
|
32
Agios Pharmaceuticals
AGIO
$2.19B
| – | – |
-21,000
| Closed | -$1M |
|
|
33
Advanced Micro Devices
AMD
$264B
| – | – |
-100,000
| Closed | -$4.59M |
|
34
Boeing
BA
$177B
| – | – |
-1,500
| Closed | -$489K |
|
35
BP
BP
$90.8B
| – | – |
-12,532
| Closed | -$473K |
|
|
CLLS
36
Cellectis
CLLS
$258M
| – | – |
-17,000
| Closed | -$291K |
|
37
CRISPR Therapeutics
CRSP
$4.71B
| – | – |
-10,000
| Closed | -$609K |
|
|
38
Caesars Entertainment
CZR
$5.57B
| – | – |
-80,000
| Closed | -$4.77M |
|
39
Editas Medicine
EDIT
$231M
| – | – |
-15,000
| Closed | -$444K |
|
40
Esperion Therapeutics
ESPR
$448M
| – | – |
-20,000
| Closed | -$1.19M |
|
41
Heron Therapeutics
HRTX
$207M
| – | – |
-50,000
| Closed | -$1.18M |
|
42
Illumina
ILMN
$15.8B
| – | – |
-5,000
| Closed | -$1.66M |
|
43
Labcorp
LH
$23.1B
| – | – |
-5,600
| Closed | -$947K |
|
44
Medtronic
MDT
$119B
| – | – |
-15,000
| Closed | -$1.7M |
|
45
Merck
MRK
$210B
| – | – |
-6,240
| Closed | -$568K |
|
46
Neurocrine Biosciences
NBIX
$13.8B
| – | – |
-9,000
| Closed | -$967K |
|
|
PARA
47
DELISTED
Paramount Global Class B
PARA
| – | – |
-88,000
| Closed | -$3.69M |
|
48
Thermo Fisher Scientific
TMO
$186B
| – | – |
-5,000
| Closed | -$1.62M |
|
|
49
Take-Two Interactive
TTWO
$43B
| – | – |
-37,700
| Closed | -$4.62M |
|
50
TherapeuticsMD
TXMD
$12.8M
| – | – |
-250,000
| Closed | -$605K |
|